Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mark Findeis"'
Autor:
Xiangmin Lv, Jesse Martin, Heather Hoover, Bishnu Joshi, Margaret Wilkens, David A. Ullisch, Thomas Leibold, John S. Juchum, Sanket Revadkar, Barbara Kalinovska, Justin Keith, Adam Truby, Gui Liu, Elaine Sun, John Haserick, Jon DeGnore, Joseph Conolly, Adrian V.S. Hill, John Baldoni, Charlotte Kensil, Dan Levey, Alexandra J. Spencer, Gilbert Gorr, Mark Findeis, Antoine Tanne
Publikováno v:
iScience, Vol 27, Iss 3, Pp 109006- (2024)
Summary: Many vaccines, including those using recombinant antigen subunits, rely on adjuvant(s) to enhance the efficacy of the host immune responses. Among the few adjuvants clinically approved, QS-21, a saponin-based immunomodulatory molecule isolat
Externí odkaz:
https://doaj.org/article/4ce190e0d41a4a90adc8bb0b7532bfc5
Autor:
Nicholas Wilson, Richard Carvajal, Irina Shapiro, Anthony Tolcher, Dhan Chand, Marc Van Dijk, Anna Wijatyk, Jennifer Buell, James Strauss, Claire Galand, Vignesh Venkatraman, Marilyn Marques, Min Lim, Benjamin Morin, Olga Ignatovich, Mark Findeis, Dennis Underwood, Lernik Ohanjanian, David Savitsky
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/91057e4b0fe44f10b2f362fe7939da70
Autor:
Nicholas S. Wilson, Dhan Chand, Min Lim, Dennis J. Underwood, Anthony W. Tolcher, Irina M. Shapiro, Anna Wijatyk, Mark Findeis, David Savitsky, Richard D. Carvajal, Jennifer Buell, Vignesh Venkatraman, Lernik Ohanjanian, James Strauss, Marc Van Dijk, Marilyn Marques, Claire Galand, Olga Ignatovich, Benjamin Morin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background CD137 (4-1BB) represents a costimulatory pathway that promotes T, NK, and dendritic cell effector functions favorable for antitumor immunity. The extracellular domain of CD137, comprised of four cysteine-rich domains (CRD-I, CRD-II, CRD-II
Autor:
Dhan Chand, Benjamin Morin, Jennifer Buell, Ekaterina Breous-Nystrom, Jeremy D. Waight, Jedd D. Wolchok, Taha Merghoub, Elise Drouin, Nicholas S. Wilson, Christopher Clarke, Marc Van Dijk, Christopher D. Dupont, Cornelia Anne Mundt, David Savitsky, Andrea Schuster, Mark Findeis, Dennis J. Underwood, Benjamin Duckless, Mariana Manrique, Rebecca Ward, Gerd Ritter, Randi Gombos, Ana M. Martín González, Robert Stein, Jean Marie Cuillerot, Hao Tang, David Schaer
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0191926 (2018)
PLoS ONE
PLoS ONE
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells. Anti-CTLA-4 antibodies enhance tumor-specific immunity through a variety o
Autor:
Randi Gombos, Matthew Costa, Claire Galand, Nicholas S. Wilson, Olga Ignatovich, Cailin E. Joyce, Dennis J. Underwood, David Savitsky, Benjamin Morin, Vignesh Venkatraman, Cornelia Anne Mundt, Min Lim, Christina Riordan, R.B. Stein, Rebecca M. Ward, Yanping Xiao, Dhan Chand, Mark Findeis, Marc van Dijk
Publikováno v:
Journal of Clinical Oncology. 37:e14005-e14005
e14005 Background: Agonist antibodies targeting CD137 are potent inducers of tumor-reactive T cell proliferation, cytokine production, and cytotoxicity, and have been explored clinically for their ability to enhance immune cell-mediated destruction o
Autor:
Joseph Connolly, Robert Stein, Reid Huber, Nicholas S. Wilson, Ekaterina Breous-Nystrom, Mark Findeis, Priyadarshini Iyer, Marc van Dijk, Peggy Scherle, Dennis J. Underwood, Christina Riordan, Horacio Nastri, Gregory Hollis, Michele Sanicola-Nadel, Jeremy D. Waight
Publikováno v:
Cancer Research. 78:3825-3825
Unprecedented rates of durable clinical responses have been observed for antibody-based therapeutics targeting immune checkpoint proteins such as cytotoxic T lymphocyte antigen-4 (CTLA-4) or programmed death receptor-1 (PD-1). Nonetheless, a signific
Autor:
Shawn Jennings, Horacio Nastri, Peggy Scherle, Reid Huber, Christina Riordan, Robert Stein, Rebecca M. Ward, Joseph Connolly, Nicholas S. Wilson, Marc van Dijk, David Savitsky, Dennis J. Underwood, Gregory Hollis, Michele Sanicola, Cornelia Anne Mundt, Mark Findeis
Publikováno v:
Cancer Research. 78:3819-3819
Lymphocyte activation gene 3 (LAG-3) is a cell surface receptor that negatively regulates antigen-specific T cell responses. LAG-3 expression is generally restricted to populations of recently activated and chronically stimulated exhausted T cells, a
Autor:
Jennifer Buell, David Savitsky, John C. Castle, Xia Yang, Jeremy D. Waight, Gerd Ritter, Mithun Khattar, Randi Gombos, Jean-Marie Cuillerot, Ana M. Martín González, John M. Goldberg, Robert Stein, David Schaer, Nicholas S. Wilson, Dhan Chand, Daniel L. Levey, Antoine Tanne, Marc van Dijk, Benjamin Morin, Mark Findeis, Taha Merghoub, Elise Drouin
Publikováno v:
Cancer Research. 77:3654-3654
Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) play important non-redundant roles in negatively regulating T cell immune responses. Therapeutic blockade of CTLA-4 or PD-1 pathways has been demonstrated
Autor:
Daniel L. Levey, Mohamed Uduman, Antoine Tanne, Paisley T. Myers, Benjamin Morin, Jeffrey Raizer, Dennis J. Underwood, Shiwen Lin, Robert Stein, Mithun Khattar, Donald F. Hunt, Bishnu P. Joshi, Victor H. Engelhard, John C. Castle, Sandra Craig, Nicholas S. Wilson, Armen Karapetyan, Elise Drouin, Mark Findeis, Jennifer Buell, Erin D. Jeffery, John M. Goldberg, Amy Yang, Mark Cobbold
Publikováno v:
Cancer Research. 77:4609-4609
Most cancer cells carry mutations unique to the patient’s individual tumor and shared biochemical signatures that are not present in healthy cells. Agenus has three vaccine platforms designed to treat cancers based on the unique needs of a given pa
Autor:
Benjamin Morin, R.B. Stein, Armen Karapetyan, Bishnu P. Joshi, Mohamed Uduman, Daniel Levey, Jeffrey Raizer, Amy Yang, Nicholas S. Wilson, Antoine Tanne, Shiwen Shiwen, Elise Drouin, John C. Castle, Sandra Craig, Jennifer Buell, Mithun Khattar, John M. Goldberg, Justin Zelin, Mark Findeis
Publikováno v:
Cancer Immunology Research. 4:A037-A037
Agenus is clinically testing Prophage™, an individualized tumor vaccine which uses heat-shock proteins endogenously complexed to neo-antigens harvested from the patient's own tumor. Agenus' genomics and bioinformatics unit rapidly identifies potent